Tirzepatide compound: the science behind the medicine

Step 1: understanding what tirzepatide actually is as a compound

Tirzepatide belongs to a class of medicines sometimes grouped under the broader GLP-1 banner, but it is more precise than that label suggests. It is a synthetic peptide, a short chain of amino acids engineered to mimic and activate two naturally occurring gut hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both play a role in signalling fullness after a meal, slowing the rate at which food leaves the stomach, and regulating blood sugar. Activating both pathways together is what distinguishes tirzepatide from older compounds such as semaglutide, which acts only on GLP-1.

In practice, this dual action means the appetite-regulating signal is stronger and works through two complementary mechanisms rather than one. The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and found average weight reductions of around 20–21% at the highest dose over 72 weeks, results that directly informed NICE's recommendation of tirzepatide for weight management in the UK. The compound itself is unchanged across every licensed pen; only the dose differs.

One practical habit worth building early: before you start any treatment, spend a minute checking that the pharmacy you are considering is listed on the GPhC pharmacy register. It takes under a minute and confirms you are dealing with a regulated, legally operating pharmacy. This single check filters out the vast majority of sellers offering unlicensed or counterfeit products.

Step 2: why searches for “compounded tirzepatide” appear, and what UK law actually says

In the United States, temporary shortages of branded tirzepatide led some compounding pharmacies to produce their own versions of the compound, and this generated a wave of search traffic that has crossed into UK searches. The legal position in the UK is straightforward: tirzepatide is a Prescription-Only Medicine licensed exclusively in its branded Mounjaro form. There is no MHRA authorisation for a compounded version, and UK pharmacy regulation does not permit compounding as a route around a licensed product that is available.

The NHS medicines page for tirzepatide describes the medicine in its licensed form, as Mounjaro. Any seller offering tirzepatide described as a “compound,” a “compound injection,” or an unlicensed preparation should be treated as a serious red flag. The MHRA has issued repeated warnings about counterfeit and illegally traded weight-loss medicines, with enforcement operations in 2025 resulting in the seizure of approximately 20 million doses of illicit product with a street value of around £45 million. Fake pens have been found to contain incorrect substances, including insulin, which can cause life-threatening harm.

If a price looks implausibly low or a seller is operating through social media without a visible GPhC registration, those are signals to walk away. Report suspect sellers through the Yellow Card scheme at yellowcard.mhra.gov.uk.

Step 3: who the licensed compound is for and how prescribing works

Tirzepatide as Mounjaro is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not determine suitability; the prescriber weighs up the full picture, including medical history, current medicines, and whether there are any contraindications.

Treatment starts at the 2.5 mg dose (a level chosen to give your body time to adjust) and is typically increased in four-week steps under prescriber oversight, with our tirzepatide l guide covering what to expect as you move through the lower titration stages. The maximum licensed dose is 15 mg. Missed doses, timing of dose changes, and any questions about the titration schedule should always be directed to your prescriber and the Patient Information Leaflet, not to general guidance.

For more background on how the treatment fits into the broader landscape of weight management options, the tirzepatide overview covers the mechanism and evidence in depth. Details about the company behind tirzepatide (Eli Lilly) and the medicine's development history are also worth reading if you want the fuller picture before making a decision. Cost is a reasonable practical question too; an honest breakdown of what private treatment involves is on the Mounjaro cost page.

Step 4: getting the genuine compound through a regulated route

The safest and legal route to tirzepatide in the UK runs through a GPhC-registered pharmacy and a valid prescription from a registered prescriber. At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber (a named clinician, not an automated system) on the same day it is submitted. Prescriptions are issued only where the clinical picture supports them.

People who have read about Mounjaro versus tirzepatide as if they are two different things sometimes arrive at consultation uncertain which they should be asking for. They are the same compound; Mounjaro is simply the brand name under which it is sold and licensed in the UK. Our prescribers handle that question regularly, and those approaching the higher end of the titration schedule may also find our tirzepatide 30 page useful for understanding what that stage of treatment involves. If you are exploring whether treatment is right for you, a look at the weight management treatment overview sets out the options clearly, and our clinical approach explains how oversight works in practice.

Treatment is dispatched through the licensed UK supply chain, in plain tracked packaging, delivered to your door the next working day once clinically approved.